Gastric & Breast Cancer e-journal
DOI: 10.2122/gbc.2010.0143
OPINION
|
Trastuzumab: Isolated success in the adjuvant setting and a paradigm for moving toward network oncology
|
|
Affiliation: Department of Molecular Biology and Genetics, Metropolitan Hospital, Athens, Greece.
|
ABSTRACT
Trastuzumab represents the greatest clinical success among all targeted agents currently available for the treatment of many solid cancer types. Despite this success, the absolute overall survival benefit is ~ 10-15% only. Indeed, phase III randomized trials in HER2-positive patients with breast cancer or gastric cancer treated with addition of trastuzumab to chemotherapy increased the overall survival gain from 30% with cytotoxic agents alone to 45% with combined chemotherapy-trastuzumab regimen. Here I discuss the results of clinical trials. Assessing resistance to the present generation of targeted drugs, I describe the challenges and future perspectives of moving of biology and molecular research from single components of biological systems towards a comprehensive systems biology-based approach.
(Citation: Gastric & Breast Cancer 2010
Oct ; 9(4):
193-198)
|
|
| You can have an online full-text access and a PDF of this article: |
- Either purchase this paper for €33 EUR. Please, click here
|
|
- Or through one year subscription PayPal
|
|
Online
ISSN : 1109 - 7647
Print ISSN : 1109 - 7655
 We
subscribe to the HONcode principles. Verify
here.
please, read our policy about privacy
and confidentiality of information and transparency
of sponsorship
last
update: 1 December 2010 |
|
